Business Context and Reporting Period
Company: ESPEY MFG. & ELECTRONICS CORP.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: The Company designs and manufactures specialized electronic power supplies, transformers, and iron-core components primarily for defense, aerospace, and industrial applications. It operates on a "build to print" or full design basis for government and industrial clients.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2005 | Nine Months Ended Mar 31, 2005 | Balance Sheet (Mar 31, 2005) |
|---|---|---|---|
| Net Sales | $4,219,861 | $13,846,929 | - |
| Gross Profit | $650,890 (15.4% margin) | $2,072,419 (15.0% margin) | - |
| Operating Income | $85,745 (2.0% margin) | $326,057 (2.4% margin) | - |
| Net Income | $111,987 | $339,603 | - |
| Diluted EPS | $0.11 | $0.33 | - |
| Cash & Equivalents | - | - | $10,159,787 |
| Short-term Investments | - | - | $2,688,000 |
| Total Assets | - | - | $29,085,585 |
| Total Liabilities | - | - | $1,558,984 |
| Working Capital | - | - | $24,813,789 |
| Operating Cash Flow (9mo) | - | $516,028 | - |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 31% for the three months and 18.9% for the nine months ended March 31, 2005, compared to the prior year. This is attributed to lower backlog levels carried over from the previous fiscal year.
- Margin Improvement: Despite lower sales, gross profit margins improved (15.4% vs. 11.7% for the quarter; 15.0% vs. 13.7% for the nine months). This was driven by a favorable product mix and the elimination of ESOP contribution expenses ($0 in 2005 vs. $134,413 in the prior quarter).
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by $106,430 for the quarter and $159,610 for the nine months, primarily due to lower professional fees and reduced ESOP costs.
- Increased Investment Income: Other income rose significantly due to higher returns on short-term investments and cash equivalents.
- Backlog Growth: While sales were down, new orders received in the fourth quarter of fiscal 2005 increased the backlog to approximately $33.1 million as of May 16, 2005, up from $14.7 million in February 2005.
Outlook, Risks, and Management Commentary
- Outlook: Management is optimistic, citing $12.7 million in new orders for the first nine months and an additional $20.0 million in the fourth quarter. Outstanding quotations exceed $26.2 million. Shipments from recent orders are expected over the next four years.
- Liquidity: The Company maintains strong liquidity with over $12.8 million in cash and short-term investments. A $3.0 million line of credit is available if needed. Working capital is expected to fund operations, dividends, and growth.
- Capital Allocation: The Company repurchased 8,724 shares of common stock for $215,366 during the nine-month period. Approximately $327,200 remains authorized for future repurchases. Dividends paid were $455,042 for the period.
- Risks & Contingencies:
- Customer Technical Issues: The Company is resolving technical problems with one customer. Costs are being shared, and no liability claims have been asserted to date.
- Government Dependence: Business is subject to U.S. and foreign government appropriations and potential order terminations.
- Standby Letters of Credit: Contingent liabilities of $39,300 exist for contract performance guarantees.
Investor Verification Checklist
- Verify the sustainability of the backlog growth ($33.1 million) and the conversion rate of outstanding quotations ($26.2 million) into firm orders.
- Monitor the resolution of technical issues with the specific customer mentioned to ensure no future cost overruns or contract terminations.
- Assess the impact of the elimination of ESOP contribution expenses on future profitability comparisons.
- Review the timing of revenue recognition for the new long-term orders to understand future cash flow patterns.
- Confirm the Company's ability to maintain gross margins as product mix shifts from mature programs to new development contracts.